Next Generation of CAR-T Therapies in Lymphoma

Data from the phase 3 CHRONOS-4 study highlight that copanlisib did not reach the primary end point of progression-free survival among patients with relapsed follicular lymphoma.

Robert Stuver, MD, and Zachary D. Epstein-Peterson, MD, spoke with CancerNetwork® about a review article on the treatment of peripheral T-cell lymphoma published in the journal ONCOLOGY®.

Sobuzoxane plus etoposide and rituximab may be safe and effective in a subgroup of elderly patients with diffuse large B-cell lymphoma and low tumor burden.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Treatment with EX103 produces deep responses among heavily pretreated patients with B-cell non-Hodgkin lymphoma across multiple subgroups in a phase 1 trial.

Data from the phase 3 ECHELON-1 trial support the European Commission’s approval of brentuximab vedotin plus chemotherapy as a treatment for those with CD30-positive stage III Hodgkin lymphoma.